Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $18.13.

A number of research analysts recently issued reports on ATEC shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Monday, April 14th. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 target price on shares of Alphatec in a report on Friday, May 2nd. Piper Sandler reiterated an "overweight" rating and issued a $15.00 target price (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 target price for the company in a report on Monday, June 16th.

Insiders Place Their Bets

In other Alphatec news, Director Karen K. Mcginnis sold 3,963 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $12.11, for a total value of $47,991.93. Following the completion of the transaction, the director directly owned 68,709 shares of the company's stock, valued at $832,065.99. This represents a 5.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Craig E. Hunsaker sold 186,122 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total transaction of $2,296,745.48. Following the completion of the transaction, the executive vice president directly owned 1,463,896 shares of the company's stock, valued at approximately $18,064,476.64. The trade was a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 299,547 shares of company stock valued at $3,698,956 in the last quarter. 20.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alphatec

Several large investors have recently modified their holdings of ATEC. Wealth Enhancement Advisory Services LLC lifted its holdings in Alphatec by 301.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock worth $608,000 after acquiring an additional 45,027 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after acquiring an additional 2,306 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Alphatec by 28.3% in the first quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company's stock worth $577,000 after acquiring an additional 12,553 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Alphatec by 13.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock worth $133,000 after acquiring an additional 1,552 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Alphatec by 6.9% in the first quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock worth $1,508,000 after acquiring an additional 9,661 shares during the last quarter. Institutional investors own 66.35% of the company's stock.

Alphatec Price Performance

Shares of NASDAQ:ATEC traded down $0.14 during midday trading on Thursday, hitting $10.49. The company had a trading volume of 1,183,969 shares, compared to its average volume of 2,077,879. Alphatec has a twelve month low of $4.88 and a twelve month high of $13.14. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -9.12 and a beta of 1.05. The business's 50-day simple moving average is $11.70 and its 200-day simple moving average is $11.08.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The business had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The company's revenue was up 22.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.34) earnings per share. As a group, sell-side analysts forecast that Alphatec will post -1.08 EPS for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.